Patents Assigned to ProQR Therapeutics II B.V.
  • Oligonucleotide therapy for leber congenital amaurosis
    Patent number: 10421963
    Abstract: Antisense oligonucleotides target the mutation in intron 26 of the CEP290 gene and reduce inclusion of the aberrant exon into the CEP290 mRNA. The oligonucleotides include no more than 3 consecutive guanosines, have no more than 60% guanosine nucleobases, include at most one CpG sequence, and/or do not have the potential to form a hairpin comprising 3 or more consecutive complementary base pairs.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: September 24, 2019
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Patricia Coromoto Biasutto, Hee Lam Chan
  • Method for increasing the activity of a cystic fibrosis transmembrane conductance regulator protein
    Patent number: 9994856
    Abstract: The present invention relates to the field of gene therapy, more specifically to oligonucleotides for making a change in the sequence of a target RNA molecule present in a living cell.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: June 12, 2018
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Daniel Anton De Boer, Tita Ritsema
  • OLIGONUCLEOTIDES FOR GENOMIC DNA EDITING
    Publication number: 20170327821
    Abstract: A method for making a change in an endogenous chromosomal DNA sequence of a mammalian cell, comprising steps of: (i) introducing into said cell an oligonucleotide having a sequence that is complementary to the chromosomal DNA sequence and that includes the change; (ii) allowing sufficient time for the cell to incorporate the change into the endogenous chromosomal DNA sequence through endogenous nucleic acid modifying pathways; and (iii) identifying the presence of the change in the chromosomal DNA sequence. The invention is particularly useful for correcting mutations in the CFTR gene.
    Type: Application
    Filed: October 23, 2015
    Publication date: November 16, 2017
    Applicant: ProQR Therapeutics II B.V.
    Inventors: Maarten Holkers, Jim Swildens
  • Oligonucleotides for making a change in the sequence of a target RNA molecule present in a living cell
    Patent number: 9605255
    Abstract: The present invention relates to the field of gene therapy, more specifically to oligonucleotides for making a change in the sequence of a target RNA molecule present in a living cell.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: March 28, 2017
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Daniel Anton De Boer, Tita Ritsema